{"id":"W2952717710","doi":"10.1136/annrheumdis-2019-eular.418","title":"AB0454 FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada); Université Laval; Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Tolerability; Tofacitinib; Internal medicine; Adverse effect; Rheumatoid arthritis; Placebo; Combination therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005948237,0.0002675591,0.0009171195,0.0004906114,0.0002420901,0.000412613,0.0001460676,0.0003525814,0.001536042],"category_scores_gemma":[0.001585713,0.0001445879,0.0008717959,0.0005567566,0.0001105278,0.0002959294,0.0001531496,0.0005607319,0.0001977221],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002795625,"about_ca_system_score_gemma":0.0002638102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000765479,"about_ca_topic_score_gemma":0.001598472,"domain_scores_codex":[0.9993668,0.0001513312,0.000105712,0.0001024222,0.0001677981,0.0001060283],"domain_scores_gemma":[0.9987801,0.0002885917,0.0005803353,0.00003918185,0.0001070358,0.000204779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01537735,0.000493777,0.9338703,0.00026165,0.001340635,0.000939092,0.00009417503,0.0002488862,0.004981021,0.00003842806,0.0006508254,0.04170386],"study_design_scores_gemma":[0.0002741068,0.002933021,0.9933726,0.00002825107,0.000497803,0.001508218,0.00007407364,0.0002828956,0.0001983874,0.0000341292,0.0007825186,0.00001400011],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926596,0.005254645,0.00009159208,0.00008143323,0.00004227643,0.00001958616,0.0003123573,0.000008743007,0.001529685],"genre_scores_gemma":[0.9984611,0.0006944371,0.00008847932,0.0001085828,0.00005519565,0.00001364234,0.00022893,0.000001905046,0.0003476763],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001536042,"threshold_uncertainty_score":0.005138576,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01284885096646849,"score_gpt":0.2732319587072943,"score_spread":0.2603831077408258,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}